Bourbon County Clerk sues county commission
BOURBON CO., Kan. — The newly elected Bourbon County Clerk sued the Bourbon County Commissioners and won, at least for now.
Susan Walker, who has been employed with Bourbon County since 2021 as the finance director, was a contract employee with a salary of $95,000 per year. She sued the commissioners in February for breach of contract and violation of the Kansas wage payment act.
According to court records, last year, commissioners told Walker her position was being eliminated.
In her petition, Walker says the commissioners told her she should run for elected office, due to the elimination of her position, and that her salary would 'follow' her. Walker did run for office and was elected county clerk, and when she didn't receive the 95k salary, she sued.
Bourbon County Clerk sues county commission
KDOT closes K-7 to through traffic between U.S. 69 and K-47
Historic site showcases life during the Civil War era
Fort Scott Airport seeks help after vehicle damages property
Joplin Humane Society accepts animals from storm damaged Nevada shelter
The commissioners didn't answer the lawsuit, and Walker was awarded a default judgment of just over $199,000.
Today, the commissioners filed a motion to set aside the judgment, claiming the lawsuit was not properly served to the appropriate person or persons. Walker has not yet received the money, and a next court date has not yet been set.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 'Company,' 'we,' 'us,' or 'our') within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Without limiting the foregoing, we may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'forecast,' 'guidance,' 'outlook,' 'may,' 'can,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ('FDA') approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ('EMA') approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS InvestorsIR@ ext. 150 MediaPR@ 650-260-7120 ext. 150Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Itron Publishes 2024 Corporate Sustainability Report
Advances Emissions Goals, Completes Double Materiality Assessment and Highlights Positive Customer Impact LIBERTY LAKE, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today released its 2024 Corporate Sustainability Report. The report details Itron's environmental, social and governance (ESG) strategy and highlights how the company is empowering cities and utilities to boost efficiency, reduce emissions and build climate-resilient communities equipped to tackle a range of challenges including resource scarcity and infrastructure strain. 'At Itron, sustainability is a responsibility we embrace every day,' said Tom Deitrich, president and CEO of Itron. 'This year, Itron completed our first enterprise-wide double materiality assessment, furthering our commitment to ensure our sustainability priorities are aligned with stakeholder expectations and regulatory requirements. Just as importantly, our solutions continued to help customers reduce their own environmental impact. We remain deeply committed to creating lasting, positive change for our business, our communities and the planet.' Key areas of progress highlighted in the 2024 Corporate Sustainability Report include: Double Materiality Assessment: Itron completed the company's first Double Materiality Assessment (DMA) in 2024. The assessment included a multiphase approach to evaluate sustainability topics through both impact and financial materiality lenses. This exercise reinforces our commitment to stakeholder engagement and helps ensure our sustainability strategy is aligned with our business priorities and future regulatory requirements. Providing Sustainable Solutions: Itron's grid edge intelligence and smart city solutions continue to help customers advance their sustainability initiatives, reduce emissions and enhance customer engagement. In 2024, Itron solutions helped customers avoid more emissions than ever before with 7.5 million metric tons of greenhouse gas emissions avoided. These reductions were driven by improved operational efficiency and increased consumer engagement. Improving Our Environmental Impact: In 2024, Itron strengthened its sustainability program through key operational milestones. Itron achieved 100% ISO 14001 certification across all manufacturing facilities and maintained impeccable safety performance. Itron has reduced its Scope 1 and 2 emissions by over 50% since 2019. Supporting Our People and Communities: Itron continued to prioritize a people-first culture in 2024, earning recognition from Newsweek and U.S. News & World Report as one of America's Greatest Workplaces. In a company-led survey, nearly 95% of employees expressed their intent to stay with the company. Itron expanded its global inclusion efforts, strengthened leadership development programs and launched early-career and apprenticeship initiatives. The company also invested over $1 million in corporate philanthropy, educational outreach and volunteerism, reinforcing Itron's role as a responsible employer and a meaningful community partner. Operating with Integrity: Ethical conduct remains central to Itron's operation. In 2024, 100% of employees completed the Code of Conduct training, and nearly 90% of the Board remained independent, ensuring strong oversight. The company also earned recognition from MSCI and Sustainalytics for maintaining a low-risk ESG profile, demonstrating Itron's values-driven leadership and growing trust among stakeholders. ESG credibility remained strong, with an 'AA' MSCI rating and a 'Low Risk' designation from Sustainalytics. Itron's 2024 report underscores its continued leadership in responsible business practices and climate action. With oversight from its board of directors and active engagement across the organization, Itron's ESG strategy remains embedded in its operations. The full 2024 Corporate Sustainability Report is available for download at About Itron Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: Itron® and the Itron logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners, and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated. Additional Resources LinkedIn: X: Newsroom: Blog: Media Contact:Alison MallahanSenior Manager, Corporate Communications(509) 891-3802PR@ Investor Contact:Paul VincentVice President, Investor Relations512-560-1172Investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
China's maritime lead a security threat, say ‘Zero Point Four' authors
A significant decline in the number of U.S.-flagged vessels and the collapse of domestic shipbuilding have created vulnerabilities in national security, say two of the co-authors of 'Zero Point Four: How U.S. Leadership in Maritime Will Secure America's Future.' James Watson and Carleen Lyden Walker said the U.S. maritime industry is at a critical moment. U.S.-flagged ships have declined to a 0.4% (200 ships) of the estimated 55,000 oceangoing vessels serving the global supply chain. 'We have lost our [maritime] leadership as a nation and we can recapture that if we decide to recognize the incredible impact of maritime security on national security, economic, energy, and food, climate and workforce,' Walker told FreightWaves in an interview. Watson and Walker said the U.S. has become so dependent on foreign-manufactured ships that it has created vulnerability in supply chains and risks shortages in military maritime than 90% of the world's goods and energy travel by ship, and most people don't understand the U.S. dependency on the maritime industry, the authors said. 'The big part of why we wrote the book … is all the opportunities that actually do exist for investments by Americans into American ships, but also industries that involve the oceans, that involve what we call the fourth industrial revolution, the use of AI, the use of the developments in science and technology that ought to be opportunities for America to basically leapfrog China,' Watson said. Watson is a retired Rear Adm. in the U.S. Coast Guard and is currently an independent consultant providing business development services to maritime clients. Walker is co-founder and managing partner of the Maritime Accelerator for Resilience and co-founder and CEO of the North American Marine Environment Protection Association.'Zero Point Four' was published in March 2024. In addition to Watson and Walker, the book was co-authored by global supply chain specialist Jonathan Kempe; technology and sustainability economist Nishan Degnarain; enterprise resilience veteran Rich Mason; and Anuj Chopra, managing director of the MaritimESG Middle East Project Management LLC. While the trade war between China and the United States appears to be cooling off in recent weeks, the nation's push to revitalize the nation's shipbuilding industry is gaining momentum. In February, the White House proposed port fees for China-built, -owned and -operated ships docking at American ports. The fees aim to minimize China's maritime dominance and help kick-start U.S. shipbuilding. The initial proposal called for vessels operated by Chinese companies to pay a $1 million port call fees and ships built in China would have to pay a $1.5 million fee per port call. The proposal now calls for fees based on net tonnage and number of containers carried. The Office of the U.S. Trade Representative also recently announced exemptions from the fees for ships carrying liquified natural gas. The USTR is accepting comments through July 7 from the maritime community on the impact of port fees associated with Chinese ships. New fees proposed by the USTR are set to take effect on Oct. 14. President Donald Trump also signed an executive order on April 9 that aims to boost the U.S. international maritime presence, which has been in decline for decades. On April 20, a bipartisan bill — the Shipbuilding and Harbor Infrastructure for Prosperity and Security for America Act of 2025 (the SHIPS Act) — was introduced in Congress with the aim of expanding the U.S.-flag international fleet by 250 ships in 10 years, while enhancing U.S. competitiveness and making more investments in the maritime workforce.A predecessor bill, the SHIPS for America Act of 2024, garnered bipartisan support last year during the Biden administration. Walker said placing fees on Chinese-built ships might ultimately hurt American consumers instead of creating more domestic ship production in the U.S. 'Passing the cost of our deficiency on to the consumer, which is what will happen with these taxes, if you will, on Chinese-built ships, I don't know how viable that is,' Walker said. 'It's like tariffs: The ultimate payor is going to be the American consumer.' Walker said a more viable proposal could be a tariff hike on U.S.-flagged ships doing repair work in shipyards in China. The tariff could be an impetus for U.S. ships to be repaired in domestic shipyards. U.S. officials floated the idea of imposing a 200% duty for work carried out on many U.S.-flag ships at yards in 'countries of concern,' according to the SHIPS Act. 'I think that one of the possibilities is restricting U.S.-flagged Jones Act ships from doing ship repair in China, which they do, and that could be a first step,' Walker said. Of 80,000 U.S. port calls each year, only a very small percentage are currently by U.S.-registered ships. '[The U.S.] intentionally walked away from its shipbuilding capability in the 1980s … and to blame China for recognizing an opportunity and capitalizing on it, I think is the wrong cast,' Walker said. 'I would rather see us say, 'Well, look, China in the early 1990s is when they decided to become a shipbuilding nation.' In the last 35 years, they have become the dominant shipbuilding nation with about 60% of the order book. How they got there also needs to be recognized.' Watson said for various reasons — including cost and efficiency — many companies in the U.S. in the 1970s and 1980s decided to outsource shipbuilding to countries such as Japan and South Korea initially. 'I think what happened was they just said, 'Well, we can just sacrifice that industry and we can buy ships from Korea and Japan, because they're building fine ships over there, and use our open registries to help the world globalize even more and focus on military shipbuilding,' Watson said. 'Then the Cold War ended and we looked around and took our peace dividend, balanced the budget again, and realized we didn't have a commercial shipbuilding industry anymore. So we just stuck … with the plan to buy ships from Japan and Korea, and then I think China saw the opportunity.' Walker and Watson said maritime security not only impacts national security, it impacts energy security, environmental security, economic security and workforce development. 'We think we can lead the world, but we probably shouldn't basically give away our designs and our technology to the cheapest place in the world to build,' Watson said. 'I guess just going to my position on the USTR thing … some of the things that they're doing probably have a time and a place and maybe now is the time and the place to do it.' Watson said it's critical that the government produce programs to restore the maritime industry in the U.S. 'You've got to have a program that creates investment here,' Watson said. 'If you look at the CHIPS Act, for example, where you actually have an act of Congress instead of effectively an executive decision of an agency, then you can put in some provisions that are bankable. You can have companies invest in a legislative initiative with a lot more security that it won't flip in four years compared to an executive mandate, like a tariff or a penalty on Chinese shipping.' The ultimate goal the U.S. government should be looking for is bringing in more mariners and reinvigorating the country's industrial shipbuilding complex, Watson and Walker said. 'It's the ships that come first,' Watson said. 'Then that causes an interest in terminals and shipyards and everything else. So there's been a lot of talk about … 'We've got to be more involved in the Panama Canal, we've got to stop [China's] Belt and Road Initiative.' If we just had a robust marine industry, a ship-operating industry, if we had merchant mariners, if we had the lead on marine technology, we would naturally want to own the terminals and the ships and have stakeholdings in great shipyards to service our ships.' The post China's maritime lead a security threat, say 'Zero Point Four' authors appeared first on FreightWaves.
